enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
-$0.02 today
- Market cap
- $123.98M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
Volume 2.81M
Average 1.58M
ENGN Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
enGene Holdings Inc.NASDAQ: ENGN
Depreciation & Amortization · Q2 FY2026 · quarter ended Apr 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q2 FY2026 depreciation & amortization of $180K rose 69.8% year over year, behind the +79.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +28.8% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +69.8% toward the trailing-twelve-month pace of +79.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 509K USD
- Year-over-year change
- +57.6%
- 4-year CAGR
- +17.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 509K | +57.6% |
| FY2024 | 2024-10-31 | 323K | +84.6% |
| FY2023 | 2023-10-31 | 175K | -26.5% |
| FY2022 | 2022-10-31 | 238K | -12.5% |
| FY2021 | 2021-10-31 | 272K | — |
Depreciation & Amortization vs competitors
How ENGN compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +79.6% is the highest of 10, against a peer median of -1.6%.
- Over three fiscal years its annual growth of +28.8% compares with a peer median of +3.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.68M USD | -2.6% | +2.9% | 28.9% | |
| LTM Mar 2026 | $12.36M USD | +53.3% | -27.5% | — | |
| LTM Mar 2026 | $3.44M USD | -15.5% | +19.5% | 89.4% | |
| LTM Mar 2026 | $3.06M USD | +36.2% | +7.2% | — | |
| LTM Mar 2026 | $2.93M USD | -1.6% | -0.7% | 1.4% | |
| LTM Mar 2026 | CHF 1.61M CHF | -27.3% | +2.0% | 43.6% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K USD | +79.6% | +28.8% | — |
| LTM Mar 2026 | $605K USD | +5.0% | +24.6% | — | |
| LTM Mar 2026 | $577.79K USD | — | +4.5% | 62.7% | |
| LTM Mar 2026 | $326K USD | +0.0% | +3.2% | — | |
| LTM Mar 2026 | $106K USD | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding ENGN) | — | -1.6% | +3.1% | 53.1% | |
Competitors are the stored peer set for ENGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.46M | 15.47M | 16.46M | 38.32M | 94.48M |
| Selling, General & Admin | 3.16M | 3.26M | 8.47M | 23.98M | 28.69M |
| Operating Expenses | 15.87M | 19.43M | 26.06M | 62.3M | 123.17M |
| Depreciation & Amortization | 272K | 238K | 175K | 323K | 509K |
| EBITDA | (18.15M) | (22.78M) | (94.77M) | (52.04M) | (113.8M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (15.87M) | (19.43M) | (26.06M) | (62.3M) | (123.17M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 25K | 129K | 1.12M | 10.41M | 9.43M |
| Interest Expense | 5.02M | 1.42M | 4.95M | 2.8M | 2.99M |
| Other Income / Expenses | (7.57M) | (5.01M) | (73.84M) | 7.14M | 5.86M |
| Income Before Tax | (23.44M) | (24.44M) | (99.9M) | (55.16M) | (117.3M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 22K | 17K | (19K) | 0 |
| Net Income | (23.44M) | (24.46M) | (99.92M) | (55.14M) | (117.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.01) | 0.00 | (4.24) | (1.46) | (2.29) |
| EPS (Diluted) | (0.01) | 0.00 | (4.24) | (1.46) | (2.29) |
| Weighted Avg Shares | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M |
| Weighted Avg Shares (Diluted) | 15.81M | 15.81M | 23.56M | 44.64M | 51.12M |
enGene Holdings Inc.
NASDAQ:ENGN
Intrinsic Alpha fair value
Locked
Current Price
$1.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.